Second primary lung cancers among breast cancer patients treated with anti-estrogens have a longer cancer-specific survival

L. I Han Hsu, A. N Chen Feng, Shu Huei Kao, Chia Chuan Liu, Stella Y C Tsai, L. I Sun Shih, Nei Min Chu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aim: Estrogen is thought to play an important role in lung cancer carcinogenesis and progression. The incidence and survival of second primary lung cancer among breast cancer patients with and without anti-estrogen therapy were evaluated. Patients and Methods: All women diagnosed with breast cancer and treated at the Sun Yat-Sen Cancer Center between January 2000 and December 2009 were included and followed-up for occurrence and/or death from lung cancer until December 2011. Results: Twenty-six women developed second primary lung cancer among 6,361 breast cancer patients. All but one were adenocarcinoma and none had a smoking habit. Seventeen (65.4%) patients had previously received anti-estrogen treatment. The relative risk of developing second primary lung cancer among those who have received anti-estrogens for breast cancer and those who have not was 1.01 (95% confidence interval (CI)=0.45-2.28; p=0.970). Second primary lung cancer patients who have received anti-estrogens had a longer cancer-specific survival (p=0.007). The multivariate Cox proportional hazards analysis showed that anti-estrogen therapy remained an independent prognostic factor with a hazard ratio of 0.11 (95% CI=0.01-0.97, p=0.002) for second primary lung cancer patients. Conclusion: The results of this study further support the fact that estrogen adversely affects the prognosis of patients with lung cancer. However, the role of estrogen in lung cancer carcinogenesis remains to be determined.

Original languageEnglish
Pages (from-to)1121-1127
Number of pages7
JournalAnticancer Research
Volume35
Issue number2
Publication statusPublished - Feb 1 2015

Fingerprint

Second Primary Neoplasms
Lung Neoplasms
Estrogens
Breast Neoplasms
Survival
Neoplasms
Carcinogenesis
Confidence Intervals
Solar System
Habits
Adenocarcinoma
Therapeutics
Smoking
Incidence

Keywords

  • Breast cancer
  • Estrogen
  • Incidence
  • Lung cancer
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Hsu, L. I. H., Feng, A. N. C., Kao, S. H., Liu, C. C., Tsai, S. Y. C., Shih, L. I. S., & Chu, N. M. (2015). Second primary lung cancers among breast cancer patients treated with anti-estrogens have a longer cancer-specific survival. Anticancer Research, 35(2), 1121-1127.

Second primary lung cancers among breast cancer patients treated with anti-estrogens have a longer cancer-specific survival. / Hsu, L. I Han; Feng, A. N Chen; Kao, Shu Huei; Liu, Chia Chuan; Tsai, Stella Y C; Shih, L. I Sun; Chu, Nei Min.

In: Anticancer Research, Vol. 35, No. 2, 01.02.2015, p. 1121-1127.

Research output: Contribution to journalArticle

Hsu, LIH, Feng, ANC, Kao, SH, Liu, CC, Tsai, SYC, Shih, LIS & Chu, NM 2015, 'Second primary lung cancers among breast cancer patients treated with anti-estrogens have a longer cancer-specific survival', Anticancer Research, vol. 35, no. 2, pp. 1121-1127.
Hsu, L. I Han ; Feng, A. N Chen ; Kao, Shu Huei ; Liu, Chia Chuan ; Tsai, Stella Y C ; Shih, L. I Sun ; Chu, Nei Min. / Second primary lung cancers among breast cancer patients treated with anti-estrogens have a longer cancer-specific survival. In: Anticancer Research. 2015 ; Vol. 35, No. 2. pp. 1121-1127.
@article{0c2a2e915040498396a919a7f4f0546e,
title = "Second primary lung cancers among breast cancer patients treated with anti-estrogens have a longer cancer-specific survival",
abstract = "Background/Aim: Estrogen is thought to play an important role in lung cancer carcinogenesis and progression. The incidence and survival of second primary lung cancer among breast cancer patients with and without anti-estrogen therapy were evaluated. Patients and Methods: All women diagnosed with breast cancer and treated at the Sun Yat-Sen Cancer Center between January 2000 and December 2009 were included and followed-up for occurrence and/or death from lung cancer until December 2011. Results: Twenty-six women developed second primary lung cancer among 6,361 breast cancer patients. All but one were adenocarcinoma and none had a smoking habit. Seventeen (65.4{\%}) patients had previously received anti-estrogen treatment. The relative risk of developing second primary lung cancer among those who have received anti-estrogens for breast cancer and those who have not was 1.01 (95{\%} confidence interval (CI)=0.45-2.28; p=0.970). Second primary lung cancer patients who have received anti-estrogens had a longer cancer-specific survival (p=0.007). The multivariate Cox proportional hazards analysis showed that anti-estrogen therapy remained an independent prognostic factor with a hazard ratio of 0.11 (95{\%} CI=0.01-0.97, p=0.002) for second primary lung cancer patients. Conclusion: The results of this study further support the fact that estrogen adversely affects the prognosis of patients with lung cancer. However, the role of estrogen in lung cancer carcinogenesis remains to be determined.",
keywords = "Breast cancer, Estrogen, Incidence, Lung cancer, Survival",
author = "Hsu, {L. I Han} and Feng, {A. N Chen} and Kao, {Shu Huei} and Liu, {Chia Chuan} and Tsai, {Stella Y C} and Shih, {L. I Sun} and Chu, {Nei Min}",
year = "2015",
month = "2",
day = "1",
language = "English",
volume = "35",
pages = "1121--1127",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Second primary lung cancers among breast cancer patients treated with anti-estrogens have a longer cancer-specific survival

AU - Hsu, L. I Han

AU - Feng, A. N Chen

AU - Kao, Shu Huei

AU - Liu, Chia Chuan

AU - Tsai, Stella Y C

AU - Shih, L. I Sun

AU - Chu, Nei Min

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Background/Aim: Estrogen is thought to play an important role in lung cancer carcinogenesis and progression. The incidence and survival of second primary lung cancer among breast cancer patients with and without anti-estrogen therapy were evaluated. Patients and Methods: All women diagnosed with breast cancer and treated at the Sun Yat-Sen Cancer Center between January 2000 and December 2009 were included and followed-up for occurrence and/or death from lung cancer until December 2011. Results: Twenty-six women developed second primary lung cancer among 6,361 breast cancer patients. All but one were adenocarcinoma and none had a smoking habit. Seventeen (65.4%) patients had previously received anti-estrogen treatment. The relative risk of developing second primary lung cancer among those who have received anti-estrogens for breast cancer and those who have not was 1.01 (95% confidence interval (CI)=0.45-2.28; p=0.970). Second primary lung cancer patients who have received anti-estrogens had a longer cancer-specific survival (p=0.007). The multivariate Cox proportional hazards analysis showed that anti-estrogen therapy remained an independent prognostic factor with a hazard ratio of 0.11 (95% CI=0.01-0.97, p=0.002) for second primary lung cancer patients. Conclusion: The results of this study further support the fact that estrogen adversely affects the prognosis of patients with lung cancer. However, the role of estrogen in lung cancer carcinogenesis remains to be determined.

AB - Background/Aim: Estrogen is thought to play an important role in lung cancer carcinogenesis and progression. The incidence and survival of second primary lung cancer among breast cancer patients with and without anti-estrogen therapy were evaluated. Patients and Methods: All women diagnosed with breast cancer and treated at the Sun Yat-Sen Cancer Center between January 2000 and December 2009 were included and followed-up for occurrence and/or death from lung cancer until December 2011. Results: Twenty-six women developed second primary lung cancer among 6,361 breast cancer patients. All but one were adenocarcinoma and none had a smoking habit. Seventeen (65.4%) patients had previously received anti-estrogen treatment. The relative risk of developing second primary lung cancer among those who have received anti-estrogens for breast cancer and those who have not was 1.01 (95% confidence interval (CI)=0.45-2.28; p=0.970). Second primary lung cancer patients who have received anti-estrogens had a longer cancer-specific survival (p=0.007). The multivariate Cox proportional hazards analysis showed that anti-estrogen therapy remained an independent prognostic factor with a hazard ratio of 0.11 (95% CI=0.01-0.97, p=0.002) for second primary lung cancer patients. Conclusion: The results of this study further support the fact that estrogen adversely affects the prognosis of patients with lung cancer. However, the role of estrogen in lung cancer carcinogenesis remains to be determined.

KW - Breast cancer

KW - Estrogen

KW - Incidence

KW - Lung cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84922928581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922928581&partnerID=8YFLogxK

M3 - Article

C2 - 25667502

AN - SCOPUS:84922928581

VL - 35

SP - 1121

EP - 1127

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -